ESMO Congress | Conferences

Improved Outcomes With Trastuzumab Deruxtecan is Associated With HER2 Expression Levels in HER2+ mCRC

September 21, 2021

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

CASPIAN Update Shows Continued Benefit of Durvalumab/Chemotherapy in ES-SCLC

September 21, 2021

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

Sitravatinib Plus Nivolumab Induces Durable Responses in Advanced NSCLC After ICIs, Chemotherapy

September 21, 2021

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer, Biomarkers May Predict Outcomes

September 20, 2021

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.